Calcium Supplement
Pregnancy: Safe in pregnancy — calcium requirements increase; supplement at 1–1.5g elemental calcium daily if dietary intake insufficient.
Calcium Carbonate
Brand names: Calcichew, Adcal, Calcichew D3 (with colecalciferol)
Adult dose
Dose: Calcium supplementation (osteoporosis prevention/treatment): 1–1.5g elemental calcium daily in divided doses. Calcichew 500mg tab: 2 tabs BD. Calcichew D3 Forte (500mg calcium + 400 IU D3): 1–2 tabs BD. Hypocalcaemia (mild): 1–2g elemental calcium daily orally.
Route: Oral (chew or swallow whole depending on formulation)
Frequency: Twice daily with meals (calcium carbonate requires acid for absorption — give with food)
Max: 2.5g elemental calcium daily (renal stones risk above this)
Calcium carbonate: 1250mg tablet = 500mg elemental calcium. Take with meals — requires gastric acid for dissolution and absorption. Separate from iron, bisphosphonates, levothyroxine, quinolones, and tetracyclines by at least 2 hours. Calcichew D3 Forte is the most commonly prescribed combined product in the UK for corticosteroid-induced osteoporosis.
Paediatric dose
Route: Oral
Frequency: Twice to three times daily with meals
Max: Varies by age
BNFc: Neonatal hypocalcaemia: IV calcium gluconate first-line (specialist). Oral supplementation: 1 month–4 years: 250mg BD; 5–11 years: 500mg BD; 12–17 years: 500–1000mg BD. Seek specialist paediatric opinion for hypoparathyroidism or complex metabolic bone disease.
Dose adjustments
Renal
eGFR <30: calcium carbonate used as phosphate binder (taken with meals); risk of hypercalcaemia — monitor calcium levels. Avoid if hypercalcaemia present.
Hepatic
No specific adjustment required.
Clinical pearls
- Prescribe with vitamin D for all patients on long-term corticosteroids (NICE CG146) — calcium alone is insufficient without adequate vitamin D for absorption
- Patients on PPI or H2RA: consider calcium citrate instead of carbonate — better absorbed in achlorhydria (no acid dependence for dissolution)
- Monitor serum calcium every 6 months if on combined calcium + vitamin D supplementation — hypercalcaemia risk particularly in renal impairment
- Calcichew D3 Forte is a phosphate binder in CKD — monitor phosphate as well as calcium
Contraindications
- Hypercalcaemia
- Hypercalciuria
- Calcium-containing renal stones (nephrolithiasis)
- Severe renal impairment with hypercalcaemia
Side effects
- Constipation (common)
- Nausea, GI upset
- Hypercalcaemia (if excessive dose)
- Milk-alkali syndrome (large doses with absorbable alkali)
- Renal stones (long-term high doses)
Interactions
- Bisphosphonates — chelation; separate by ≥2 hours
- Levothyroxine — reduces absorption; separate by ≥4 hours
- Iron supplements — reduces absorption of both; separate by 2 hours
- Quinolones, tetracyclines — chelation; separate by 2 hours
- Thiazide diuretics — additive hypercalcaemia risk
Monitoring
- Serum calcium (every 6 months on supplementation)
- Urinary calcium (24h collection if recurrent renal stones)
- Renal function
- Phosphate (in CKD)
Reference: BNFc; BNF 90; NICE CG146 (Osteoporosis); NICE CG182 (CKD). Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Hyperkalaemia Management Algorithm · Electrolyte Disorders
- FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma
- Corrected Calcium · Electrolytes
- Calcium-Phosphate Product · Electrolytes
- Corrected Calcium (for Albumin) · Electrolytes
- Hyperkalaemia Severity and ECG Risk · Electrolytes
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016